GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Escalon Medical Corp (OTCPK:ESMC) » Definitions » Debt-to-EBITDA

Escalon Medical (Escalon Medical) Debt-to-EBITDA : -3.05 (As of Dec. 2023)


View and export this data going back to 1993. Start your Free Trial

What is Escalon Medical Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Escalon Medical's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.38 Mil. Escalon Medical's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.33 Mil. Escalon Medical's annualized EBITDA for the quarter that ended in Dec. 2023 was $-0.23 Mil. Escalon Medical's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -3.05.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Escalon Medical's Debt-to-EBITDA or its related term are showing as below:

ESMC' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -3.48   Med: 0   Max: 118.13
Current: 0.94

During the past 13 years, the highest Debt-to-EBITDA Ratio of Escalon Medical was 118.13. The lowest was -3.48. And the median was 0.00.

ESMC's Debt-to-EBITDA is ranked better than
56.02% of 432 companies
in the Medical Devices & Instruments industry
Industry Median: 1.21 vs ESMC: 0.94

Escalon Medical Debt-to-EBITDA Historical Data

The historical data trend for Escalon Medical's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Escalon Medical Debt-to-EBITDA Chart

Escalon Medical Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.20 -3.48 118.13 14.18 1.70

Escalon Medical Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23.96 0.41 1.03 -40.00 -3.05

Competitive Comparison of Escalon Medical's Debt-to-EBITDA

For the Medical Devices subindustry, Escalon Medical's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Escalon Medical's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Escalon Medical's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Escalon Medical's Debt-to-EBITDA falls into.



Escalon Medical Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Escalon Medical's Debt-to-EBITDA for the fiscal year that ended in Jun. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.37 + 0.52) / 0.524
=1.70

Escalon Medical's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.382 + 0.325) / -0.232
=-3.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Escalon Medical  (OTCPK:ESMC) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Escalon Medical Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Escalon Medical's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Escalon Medical (Escalon Medical) Business Description

Traded in Other Exchanges
N/A
Address
435 Devon Park Drive, Suite 824, Wayne, PA, USA, 19087
Escalon Medical Corp operates in the healthcare market specializing in the development, manufacture, marketing, and distribution of medical devices and pharmaceuticals in the area of ophthalmology. Its products are A-Scans, B-Scans, UBM, Pachymeters, Color/Fluorescein Angiography Digital Imaging Systems, Ispan Intraocular Gases, Surgical Packs, Viscous Fluid Transfer Systems, and AXIS Image Management. Substantial revenue is generated from the domestic sales of products.
Executives
David James Jacovini director 120 PINE STREET, PHILADELPHIA PA 19106
John Dogum director 1818 MARKET STREET, 35TH FLOOR, PHILADELPHIA PA 19103
Richard J Depiano director 435 DEVON PARK DRIVE, SUITE 100, WAYNE PA 19087
Lisa A Napolitano director 351 EAST CONESTOGA ROAD, WAYNE PA 19087
C Sean Closkey director 1700 MARKET STREET, 19TH FLOOR, PHILADELPHIA PA 19103
C Todd Trusk director 1410 RUSSELL ROAD, SUITE 100, WAYNE PA 19301
Robert Michael O'connor officer: Chief Financial Officer 53 SORREL RUN, MT. LAUREL NJ 08054
Anthony J Coppola director 1 NORTH NEW YORK ROAD, SMITHVILLE NJ 08205
Federman Jay L Md director 501 N. ESSEX AVENUE, NARBERTH PA 19072
Kwan William L G director 351 EAST CONESTOGA ROAD, WAYNE PA 19087
Mark Wallace officer: Chief Operating Officer 565 E SWEDESFORD ROAD, STE 200, WAYNE PA 19087
Fred G Choate director 601 DELSEA DRIVE, WASHINGTON TOWNSHIP NJ 08080
Depiano Richard J Jr officer: President 575 E. SWEDESFORD ROAD, SUITE 100, WAYNE PA 19087
Berkowitz David officer: Principal Accounting Officer 565 EAST SWEDESFORD ROAD, SUITE 200, WAYNE PA 19087
Mark H Karsch officer: CFO 565 EAST SWEDESFORD ROAD, SUITE 200, WAYNE PA 19087

Escalon Medical (Escalon Medical) Headlines